Urine Metabolic Profiles: Potential Key to Diagnosing Kidney Cancer
Posted: Thursday, August 29, 2019
In a first step toward the identification of biomarkers in urine that are specific for renal cell carcinoma, researchers discovered “markedly different metabolic profiles” among 129 healthy controls, 100 patients with renal cell carcinoma, and 39 individuals with benign kidney tumors. The results, published in Frontiers in Oncology, suggest “the feasibility of utilizing urine metabolites for early clinical diagnosis,” wrote the authors.
Using metabolomics based in liquid chromatography–mass spectrometry, Xiaoyan Liu, MD, of the Chinese Academy of Medical Sciences, Beijing, and co-investigators found that in particular, N-formylkynurenine seemed to have potential as a marker to distinguish people with renal cell carcinoma from healthy and benign controls. Overall, “the changes in tryptophan metabolism have profound implications for designing new targets for renal cell carcinoma,” the scientists noted.
This was “the first attempt at applying urine metabolomics for differential diagnosis of renal cell carcinoma versus benign kidney tumors,” Dr. Liu and colleagues continued. In any future work validating their analysis, the researchers recommended diet standardization to eliminate, as much as possible, the influence of diet on urine metabolomics.
Disclosure: The study authors reported no conflicts of interest.